Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
- PMID: 36653520
- DOI: 10.1038/s41440-023-01188-z
Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
Keywords: Aldosterone synthase inhibitor; Baxdrostat; Mineralocorticoid receptor antagonist; Renin-angiotensin-aldosterone system.
Comment on
-
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20. Hypertens Res. 2023. PMID: 36266539 Free PMC article. Clinical Trial.
References
-
- Te Riet L, Van Esch JHM, Roks AJM, Van Den Meiracker AH, Danser AHJ. Hypertension: Renin-Angiotensin-Aldosterone System Alterations. Circ Res. 2015;116:960–75. - DOI
-
- Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2022;45:967–75. - DOI
-
- Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders—New perspectives for combination therapy. Pharm Res. 2021;172:105859. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
